PTEN-deficient prostate cancer patients often also harbor inactivating mutations in lysine N-methyltransferase 2C (KMT2C) and mice bearing both alterations develop prostate cancer metastases with a hallmark c-Myc gene signature [122]. The gene discussed is MYC; the disease is prostate carcinoma.